IMMUNITYBIO, INC. Total Liabilities
IMMUNITYBIO, INC. (IBRX) had Total Liabilities of $1.67 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-04
- 2026-06-30: Liabilities $1.67B.
- 2026-03-31: Liabilities $1.52B.
- 2025-12-31: Liabilities $1.00B.
- 2025-09-30: Liabilities $1.04B.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $1.67B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $1.52B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $1.00B 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $1.04B 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $971.89M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $894.24M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $871.06M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $1.11B 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $1.14B 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $1.09B 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $1.09B 10-K · filed 2025-03-03 | |
| 2023-09-30 | $843.06M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $936.41M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $875.12M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $812.18M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $782.02M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $739.69M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $727.14M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $712.82M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $404.37M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $404.89M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $394.76M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $339.87M 10-K · filed 2022-03-01 | $34.47M 10-K · filed 2021-03-04 |
| 2020-09-30 | $31.91M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $26.51M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $24.43M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $253.46M 8-K/A · filed 2021-04-22 | $22.44M 10-K · filed 2020-03-25 |
| 2019-09-30 | $24.25M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $24.43M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $40.45M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $35.94M 10-K · filed 2020-03-25 | |
| 2018-09-30 | $39.55M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $29.80M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $29.48M 10-Q · filed 2018-05-07 | |
| 2017-12-31 | $31.60M 10-K · filed 2019-03-13 | |
| 2017-09-30 | $40.03M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $48.70M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $25.31M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $24.08M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $21.52M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $15.58M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $12.93M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $10.85M 10-K · filed 2017-03-15 | |
| 2015-09-30 | $7.26M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $6.04M 10-Q · filed 2015-09-10 | |
| 2014-12-31 | $2.40M 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |